PF 07038124
Alternative Names: PF-07038124Latest Information Update: 08 May 2025
At a glance
- Originator Pfizer
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Plaque psoriasis
Most Recent Events
- 18 Feb 2025 Icahn School of Medicine at Mount Sinai terminates a phase II trial in Seborrheic dermatitis and Papulopustular rosacea in the US (Topical) (NCT06013371)
- 31 Oct 2023 Discontinued - Phase-II for Atopic dermatitis (In adolescents, In the elderly, In adults) in Japan, USA, United Kingdom, Canada (Topical) prior to October 2023
- 31 Oct 2023 Discontinued - Phase-II for Atopic dermatitis in Canada, Australia, USA (Topical) prior to October 2023